Similar articles

• Interleukin-17 and type 17 helper T cells.

  Miossec P, Korn T, Kuchroo VK. Miossec P, et al. N Engl J Med. 2009 Aug 27;361(9):888-98. doi: 10.1056/NEJMra0707449. N Engl J Med. 2009. PMID: 19710487 Review. No abstract available.
• [Prediction of efficacy of molecular targeted agents for rheumatoid arthritis].

  Izumi K, Kameda H. Izumi K, et al. Nihon Rinsho. 2012 Nov;70 Suppl 8:658-63. Nihon Rinsho. 2012. PMID: 23513918 Japanese. No abstract available.
• [Molecular targeting therapy in rheumatoid arthritis].

  Mima T, Nakashima Y, Hanba Y, Ohya M, Negi S, Shigematsu T. Mima T, et al. Nihon Jinzo Gakkai Shi. 2012;54(5):603-9. Nihon Jinzo Gakkai Shi. 2012. PMID: 22991840 Review. Japanese. No abstract available.
• Tumor necrosis factor inhibitors for rheumatoid arthritis.

  Roos JC, Ostor AJ. Roos JC, et al. N Engl J Med. 2006 Nov 9;355(19):2046-7; author reply 2048. doi: 10.1056/NEJMc062500. N Engl J Med. 2006. PMID: 17093259 No abstract available.
• New therapies for rheumatoid arthritis.

  Goldblatt F, Isenberg DA. Goldblatt F, et al. Clin Exp Immunol. 2005 May;140(2):195-204. doi: 10.1111/j.1365-2249.2005.02744.x. Clin Exp Immunol. 2005. PMID: 15807842 Free PMC article. Review.